---

Top Highlights for October 2013:  (Please click on read more to see details)

 

1.  Pieris AG, a Aagami client, signs broad co-development alliance for Novel Anticalin® Therapeutics with Zydus of India Read more
2. US-based Mylan bets $ Billions on India Pharma market  Read more
3. Biological E plans to raise $100 million via stake sale to launch new products, expands its R&D facilities and buy assets overseas 
4. UK’s CDC Group plans to invest $48.53 million in KIMS, India 
5. Symbiotec Pharmalab, India receives $48 million investment from global equity firm Actis  Read more
6. SMS Pharma, India sells their manufacturing facility to Mylan, US for $33 million  Read more
7. India’s Unichem Laboratories to sell one of its plants to Mylan for $26.3 million Read more
8. Sun Pharma, India in JV with Intrexon Corp, US to develop controllable gene-based therapies for ocular diseases,
9. India to be among the Top 5 destinations for M&A: Ernst & Young Report  Read more